Mazen Elkurd, DO


Seeking Clarity in Patient Stratification of Parkinson Disease: Mazen Elkurd, DO

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the dilemma of stratifying patients with Parkinson disease based on various criteria and emphasized the need for a consensus on classification. [WATCH TIME: 3 minutes]

Hong Sun, MD, PhD


The Potential of Nipocalimab as a Treatment for Autoantibody Mediated Diseases: Hong Sun, MD, PhD

The senior director and global compound development team leader at Janssen discussed research on nipocalimab, an investigational agent for patients with myasthenia gravis that's shown promising data to this point. [WATCH TIME: 2 minutes]

Dalia Rotstein, MD, MPH


Beginning and Transitioning DMT in MS: Dalia Rotstein, MD, MPH

The assistant professor of medicine at University of Toronto, and neurologist at St. Michael's Hospital spoke about the process of changing or beginning treatment with a variety of disease-modifying therapies in multiple sclerosis. [WATCH TIME: 4 minutes]

Ada Metaxas, BS-C


Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care

Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population: Alzheimer disease and AD-related dementias.

Shae Datta, MD


Raising Awareness for the Lasting Effects of Traumatic Brain Injury: Shae Datta, MD

The neurologist and migraine expert at NYU Langone Health provided perspective on TBI Awareness Month and the importance of accurate detection and swift care for trauamatic brain injury. [WATCH TIME: 4 minutes]

Ruth Benca, MD, PhD


Assessing the Correlations With Sleep Issues and Risk of Dementia: Ruth Benca, MD, PhD

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine provided insight on the signs and risks associated with sleep disorders and Alzheimer disease. [WATCH TIME: 3 minutes]

Susan Matulevicius, MD, MSCS


AUPN Leadership Minute Episode 19: Happy Faculty-Happy Life: Improving Faculty Satisfaction

Episode 19 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University; and Susan Matulevicius, MD, MSCS, of UT Southwestern Medical Center. [WATCH TIME: 4 minutes]

Stewart Factor, DO


The Therapeutic Pipeline for Parkinson Disease: Stewart Factor, DO

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine shared his perspective on the research and development of Parkinson therapies.

Bruce Hughes, MD


Therapy Adjustments for Optimal, Early Intervention to Prevent Neurodegeneration in MS

The multiple sclerosis (MS) experts advise health care providers on how to impact the early onset of disease progression and prevent neurodegeneration in patients with MS.

Nicola De Stefano, MD, PhD


Understanding the Clinical Advantages of Cladribine and its Impacts on Oligoclonal Bands: Nicola De Stefano, MD, PhD

The professor of neurology in the department of medicine, surgery, and neuroscience at the University of Siena, gave perspective on an analysis of the MAGNIFY-MS study, in which treatment with cladribine demonstrated impacts on CNS-related pathology in MS. [WATCH TIME: 4 minutes]

Nicholas Varvel


Broad Anti-inflammatory Approaches Feasible for Epilepsy: Nicholas Varvel, PhD

The assistant professor in the department of pharmacology and chemical biology at Emory University School of Medicine spoke about immune cells in epilepsy based on his special lecture at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]

Colin Josephson, MD, MSc, FRCPC


Clinician and Patient Collaboration Advances Research and Epilepsy Care: Colin Josephson, MD, MSc, FRCPC

The associate professor of neurology at the University of Calgary spoke about advancing epilepsy care through patient-oriented research at the 2022 AES Annual Meeting. [WATCH TIME: 6 minutes]

Rebecca Whitney


The Label of ‘Caregiver’

Rebecca Whitney, associate director of Programs and Community Support at SRNA and mother of child with a rare neuroimmune disorder, provided thoughts on the importance of caregivers and the role they play in everyday life.

Mill Etienne, MD


AUPN Leadership Minute Episode 25: Patching the Holes in the Pipeline: Strategies to Enhance Diversity, Equity and Inclusion in Neurology

Episode 25 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Mill Etienne, MD, of New York Medical College. [WATCH TIME: 8 minutes]

Courtney Young, PhD


Revolutionizing Treatment For Duchenne Muscular Dystrophy with Gene Editing: Courtney Young, PhD

The co-founder and chief executive officer of MyoGene Bio talked about the advantages of gene editing over traditional gene therapy as a long term treatment for neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 3 minutes]

Melanie Quintana, PhD


The Implementation of Platform Trials for ALS Research: Melanie Quintana, PhD

The senior statistical scientist and director of consulting at Berry Consultants talked about innovative clinical trial design in ALS research at the 2023 MDA conference. [WATCH TIME: 5 minutes]

Aparna V.R. Polavarapu, MD


Aparna V.R. Polavarapu, MD: Early Treatment for Infantile Spasms

The pediatric neurologist at Montefiore Health System explains the importance of treating infantile spasms as early as possible and how it may impact outcomes.

Stuart J. Connolly, MD, FRCPC


Key Takeaways From ANNEXA-I Study

Dr Connolly highlights the cautious patient selection and the significance of reducing hematoma expansion for improved outcomes in cases of intracerebral hemorrhage (ICH) associated with the use of a reversal agent for factor Xa inhibitors.

Rachel Alvarez


Mission Behind Cure CMD’s Research Roundtable, Efforts Around CMDs: Rachel Alvarez

The executive director of Cure CMD discussed efforts being done to bring the stakeholder community together and improve the care for patients with congenital muscular dystrophies. [WATCH TIME: 4 minutes]

Patricia Melville, RN, MSN, NP-C, MSCN


Concluding Thoughts on Biosimilars in Multiple Sclerosis

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.

Steven Arnold, MD


Steven Arnold, MD: Assessing AMX0035 Efficacy in Alzheimer Disease

The managing director of the Interdisciplinary Brain Center at Massachusetts General Hospital discussed the process of determining the best situations for use of AMX0035.

Sameea Husain-Wilson, DO


Role of Alpha-Synuclein in Accurate and Early Diagnosis of Parkinson Disease: Sameea Husain-Wilson, DO

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute discussed how the Syn-One test utilizes alpha-synuclein and what this biomarker adds to the diagnosis of Parkinson disease. [WATCH TIME: 3 minutes]

Alan Towne, MD


AUPN 2022 Veterans Health Administration Workshop

Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]

Christal Mickle


Expanding KP1077’s Clinical Program to Address Narcolepsy and Other Conditions: Christal Mickle

The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]

Jodi A. Mindell, PhD


Differences in Approaches to Pediatric and Adult Sleep Disorders: Jodi A. Mindell, PhD

The associate director of the Sleep Center at Children’s Hospital of Philadelphia detailed the similarities and differences in how sleep disorders are viewed between children and adults. [WATCH TIME: 4 minutes]

Ian Kremer
Ian Kremer


Lessons Learned From Aducanumab Experience and Antiamyloid Therapies: Ian Kremer

The executive director of the Lead (Leaders Engaged on Alzheimer’s Disease) Coalition provided thoughts on the journey and lessons learned from aducanumab (Aduhelm) following Biogen’s decision to remove it from market. [WATCH TIME: 8 minutes]

Robert W. Motl, PhD


CMSC Live: 2024 Annual Meeting Day 2

Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Jason Freeman, MD, MBA


Consistent Real-World Efficacy of Ofatumumab Therapy for Multiple Sclerosis: Jason Freeman, MD, MBA

The medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Lauren Treat, MD


Standardizing Clinical Practice for End of Life Care in Neuromuscular Diseases: Lauren Treat, MD

The child neurologist at the University of Colorado School of Medicine talked about her presentation on end of life care for patients with neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 5 minutes]

© 2024 MJH Life Sciences

All rights reserved.